Mouse anti-Human Activated C3 Monoclonal Antibody

Activated C3, Human, mAb bH6

Cat. Num. AAA584410

• Reactivity: Human
• Applications: F, Immunoassay (IA), P
• Synonyms: Activated C3; Monoclonal Antibody; Human; mAb bH6; anti-Activated C3 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Mouse IgG2a
• Form/Format: 1 ml (100 ug/ml) 0.2 um filtered antibody solution in PBS, containing 0.02% sodium azide and 0.1% bovine serum albumin.; For unit size 0.5 mg or larger: PBS only (concentration< 0.5mg/ml)

• Applicable Applications for anti-Activated C3 antibody: F, Immunoassay (IA), P
• Application Notes: Application Use: For immunohistology, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
• Preparation and Storage: Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for one year.

Related Product Information for anti-Activated C3 antibody

Product Description: The monoclonal antibody bH6 recognizes a neo-epitope expressed on the cleavage fragments of C3b, iC3b, and C3c. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b, C3c, C3dg and C3f. The monoclonal antibody bH6 is specific for a C3 neo-epitope expressed on the cleavage fragments of C3b, iC3b, and C3c, but not C3dg and C3f.

References

1. Garred, P et al; Characterization of a monoclonal antibody MoAb bH6 reacting with a neo-epitope of human C3 expressed on C3b, iC3b, and C3c. Scand J Immunol 1988, 27: 319
2. Halstensen T et al; Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990, 98: 1264
3. Garred P et al; Quantification in enzyme-linked immunosorbent assay of a C3 neo-epitope expressed on activated human complement factor C3. Scand J Immunol 1988, 27: 329
4. Lappeg¥rd, K et al; Effect of complement inhibition and heparin coating on artificial surface - induced leukocyte and platelet activation. Ann Thorac Surg 2004, 77: 932